Treatment of Parkinson’s disease aims at compensating for the deficit in dopaminergic activity and because dopamine is preferentially deaminated by MAO-B, inhibition of this isoenzyme should raise the basal central level of dopamine [56]. This evidence concerns the gene MAOB and Parkinson disease.